Tavapadon

Phase 3: large human trials

An experimental once-daily pill that targets dopamine D1/D5 receptors. Its Phase 3 TEMPO program reported meeting its main goals; it is a symptom treatment, not disease-modifying.

What it is

Tavapadon is a 'partial agonist' at the D1/D5 dopamine receptors. Most current dopamine-acting drugs hit different receptors (D2/D3); the hope with D1/D5 is meaningful symptom relief with a different, potentially smoother side-effect profile.

Where it stands

AbbVie has reported that the Phase 3 TEMPO trials met their primary endpoints, both as a standalone treatment in early disease and as an add-on to levodopa. Whether and when it is submitted to the FDA is up to the company.

What the data shows so far

The TEMPO program tested tavapadon over roughly 26 weeks. According to the company, the trials met their main endpoint of improving a standard Parkinson's rating scale (the MDS-UPDRS) versus placebo, and the add-on study increased daily 'on' time. Full peer-reviewed results are how these claims should be judged.

What families should know

If approved, this would be another option for controlling symptoms, particularly for people who don't tolerate existing dopamine agonists well. It is not designed to slow the disease.

Caveats

Results so far come substantially from company announcements; weigh peer-reviewed publications and the FDA review when available. It treats symptoms only. Dopamine-receptor drugs as a class can cause impulse-control problems (gambling, compulsive shopping) and sleepiness. The real-world rate for tavapadon will become clearer with wider use.

Timeline

Most recent first.

Sources

Last reviewed: 2026-06-01. Back to the Parkinson's drug pipeline